AF
IRON icon

Amalgamated Financial’s Disc Medicine IRON Stock Holding History

Amalgamated Financial’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$4K Buy
+97
New +$5.09K ﹤0.01% 2969

Other funds holding IRON

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amalgamated Financial's IRON Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Disc Medicine (IRON) in Q1 2022: 97 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2969 among its holdings.

57 funds tracked by Wall St. Rank hold IRON as of Q1 2022.

  • Amalgamated Financial held 97 shares of Disc Medicine worth $4K as of Q1 2022.
  • Disc Medicine was a new Amalgamated Financial position in Q1 2022.
  • Disc Medicine made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2969 holding.
  • 57 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.